论文部分内容阅读
目的:评估小梁切除术及玻璃体内注射雷珠单抗治疗新生血管性青光眼的临床效果。方法:回顾性分析余姚市妇幼保健院2017年1月至2018年12月收治的65例(65只眼)新生血管性青光眼的临床资料，患者分为两组，对照组32例，接受复合式小梁切除术及广泛视网膜光凝治疗；观察组33例，接受复合式小梁切除、玻璃体内雷珠单抗注射及广泛视网膜光凝治疗。术后随访3个月。比较两组的治疗效果。结果:观察组总有效率为96.97%(22/33)，高于对照组的75.00%(24/32)，两组间差异有统计学意义(n χ2＝4.861，n P＝0.027)。观察组术后视力提高者占96.97%(22/33)，高于对照组的71.88%(23/32)，两组间差异有统计学意义(n χ2＝6.050，n P＝0.014)。两组术后眼压均明显低于同组术前(n P<0.05)。术后观察组眼压均低于对照组(n P<0.05)。观察组新生血管消退率93.94%(31/33)高于对照组68.75%(22/32)，两组间差异有统计学意义(n χ2＝5.277，n P＝0.022)。n 结论:小梁切除术联合玻璃体内注射雷珠单抗及视网膜光凝治疗新生血管性青光眼效果良好。“,”Objective:To evaluate the clinical efficacy of trabeculectomy and intravitred injection of ranibizumab for the treatment of neovascular glaucoma.Methods:The clinical data of 65 eyes of 65 cases with neovascular glaucoma from Jan. 2017 to Dec. 2018 in Yuyao Second People’s Hospital were retrospectively analyzed. The patients were divided into two groups. The control group, 32 patients, underwent complex trabeculectomy and panretinal photocoagulation. The observation group, 33 patients, underwent complex trabeculectomy, intravitreal ranibizumab injection and panretinal photocoagulation. The follow-up time was 3 months. The therapeutic efficacy of the two groups were compared.Results:The total effective rate of the observation group was 96.97% (22/33), which was higher than that of the control group (75.00%, 24/32). The difference was statistically significant between the two groups (n χ2=4.861, n P=0.027). The visual acuity of the observation group was improved in 32 cases (96.97%, 22/33), which was higher than that of the control group (71.88%, 23/32). The difference was statistically significant between the two groups (n χ2=6.050, n P=0.014). The intraocular pressure of the two groups after surgery were significantly lower than that before surgery (n P<0.05). The intraocular pressure of the observation group was lower than that of the control group at the same time (n P<0.05). The neovascular regression rate was 93.94% (31/33) in the observation group, which was higher than that in the control group (68.75%, 22/32). The difference was statistically significant between the two groups (n χ2=5.277, n P=0.022).n Conclusion:Trabeculectomy and intravitreal injection of ranibizumab is effective in the treatment of neovascular glaucoma.